A team from the University of Bath has developed peptides capable of permanently blocking the cJun protein, which is involved ...

Collaborative research led by investigators at Dana-Farber/Boston Children's Cancer and Blood Disorders Center defines a ...

The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 programNurix DEL-AI drug ...

Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 ...

Nurix Therapeutics NRIX shares rose 8.7% on Wednesday after the company announced that Sanofi SNY has in-licensed exclusive ...

Fusarium oxysporum is a soil-borne fungal pathogen that causes a group of serious plant diseases known as Fusarium wilts. As ...

The unexpected discovery may provide scientists with new insights into how cancer develops — and how to combat it.

New research offers unprecedented insight into how an enigmatic enzyme, known as CDK7, drives the cell cycle and cell proliferation.

Researchers discovered peptides that permanently block a key cancer protein once thought untreatable, using a new screening method to test their effectiveness inside cells. For the first time, scienti ...

Nurix Therapeutics (NRIX) announced that Sanofi (SNY) has exclusively licensed an undisclosed Nurix program targeting a previously undruggable ...

Nurix Therapeutics has widened its collaboration with Sanofi, granting the French pharmaceutical company an exclusive license to an undisclosed program targeting a previously undruggable transcription ...